Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13559522 | 0.83 | HCAR3 (0.45) | HCAR3HTTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6522547 | 0.82 | HCAR3 (0.57) | HCAR3HTTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4326964 | 0.81 | HCAR3 (0.44) | HCAR3HTTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2886701 | 0.81 | HCAR3 (0.53) | HCAR3HTTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL27734810 | 0.81 | ALDH1A1 (0.44) | HCAR3HTTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13210813 | 0.80 | BRAF (0.47) | HCAR3HTTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1217486 | 0.80 | KDR (0.54) | HCAR3 | |
| SCHEMBL13788542 | 0.80 | HTT (0.56) | HCAR3HTTNPC1KMT2AMAPT | |
| SCHEMBL4330384 | 0.80 | HCAR3 (0.46) | HCAR3HTTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4326186 | 0.80 | MAPT (0.49) | HCAR3HTTRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614330-B2 | Substituted benz-azoles and methods of their use as inhibitors of RAF kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-8501785-B2 | Salts of benzimidazolyl pyridyl ethers and formulations thereof | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8501785-B2 | Salts of benzimidazolyl pyridyl ethers and formulations thereof | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8455662-B2 | Formulations for benzimidazolyl pyridyl ethers | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455662-B2 | Formulations for benzimidazolyl pyridyl ethers | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG | 2012-12-06 | — | — | US | disclosed |
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG | 2012-12-06 | — | — | US | disclosed |
| US-8324389-B2 | Solid forms of a Raf kinase inhibitor | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324389-B2 | Solid forms of a Raf kinase inhibitor | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2007-03-01 | — | — | US | disclosed |
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2007-03-01 | — | — | US | disclosed |
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2007-03-01 | — | — | US | disclosed |
| EP-1675584-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2006-07-05 | — | — | EP | disclosed |
| US-7071216-B2 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| WO-2005032548-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1499311-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | Chiron Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | ABL1, CDK2, KIT | HCAR3 2950/4885HTT 4745/4885RAB9A 2326/4885 |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | HCAR3 3234/4885HTT 4527/4885RAB9A 1662/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | HCAR3 3586/4885HTT 4400/4885RAB9A 1810/4885 |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | HCAR3 3234/4885HTT 4527/4885RAB9A 1662/4885 |
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | PIR, BRD8, PHOSPHO1 | HCAR3 4778/4885HTT 2225/4885RAB9A 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.